1.

Fig 6 -

2.

Fig 6 -

3.

Fig 6 -

4.

Fig 6 -

5.

Fig 6 -

6.

Fig 6 -

7.

Fig 6 -

8.

Fig 6 -

9.

Fig 6 -

1.

Fig 1 -

2.

Fig 1 -

3.

Fig 1 -

4.

Fig 1 -

5.

Fig 1 -

6.

Fig 1 -

7.

Fig 1 -

8.

Fig 1 -

9.

Fig 1 -

1.

Sankey diagram of the origin and genetic context of mcr -genes.

2.

Sankey diagram of the origin and genetic context of mcr -genes.

3.

Sankey diagram of the origin and genetic context of mcr -genes.

4.

Sankey diagram of the origin and genetic context of mcr -genes.

5.

Sankey diagram of the origin and genetic context of mcr -genes.

6.

Sankey diagram of the origin and genetic context of mcr -genes.

7.

Sankey diagram of the origin and genetic context of mcr -genes.

8.

Sankey diagram of the origin and genetic context of mcr -genes.

1.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

2.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

3.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

4.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

5.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

6.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

7.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

8.

Phenotypic antibiotic resistance of colistin-resistant Enterobacterales.

1.

Fig 4 -

2.

Fig 4 -

3.

Fig 4 -

4.

Fig 4 -

5.

Fig 4 -

6.

Fig 4 -

7.

Fig 4 -

8.

Fig 4 -

9.

Fig 4 -

1.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

2.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

3.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

4.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

5.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

6.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

7.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

8.

Insights into the resistance to critically important antibiotics and the number of virulence classes present in colistin-resistant isolates from different One Health sectors.

1.

Confirmatory factor analysis of the H-PEPSS model for classroom learning.

2.

Confirmatory factor analysis of the H-PEPSS model for classroom learning.

3.

Confirmatory factor analysis of the H-PEPSS model for classroom learning.

4.

Confirmatory factor analysis of the H-PEPSS model for classroom learning.

1.

Confirmatory factor analysis of the H-PEPSS model for clinical learning.

2.

Confirmatory factor analysis of the H-PEPSS model for clinical learning.

3.

Confirmatory factor analysis of the H-PEPSS model for clinical learning.

4.

Confirmatory factor analysis of the H-PEPSS model for clinical learning.

1.

We consider that an individual goes through different phases of infection/disease, which is represented by a SEIR-like state machine.

2.

We consider that an individual goes through different phases of infection/disease, which is represented by a SEIR-like state machine.

1.

Trends (average and standard deviations) for all combinations of parameters 〈 k , T d 〉, for FNR PCR = 0.1.

2.

Trends (average and standard deviations) for all combinations of parameters 〈 k , T d 〉, for FNR PCR = 0.1.

1.

Distribution of the number of infections for the experiments when the lock-down ends on the first of July, in different scenarios of compliance for testing and isolation.

2.

Distribution of the number of infections for the experiments when the lock-down ends on the first of July, in different scenarios of compliance for testing and isolation.

1.

Trends for different leisure contact reductions, when performing weekly universal testing.

2.

Trends for different leisure contact reductions, when performing weekly universal testing.

1.

Trends for different leisure contact reductions, when performing weekly universal testing, and importing 10 cases per day.

2.

Trends for different leisure contact reductions, when performing weekly universal testing, and importing 10 cases per day.

1.

Trends for different leisure contact reductions, when performing weekly universal testing, and importing 50 cases per day.

2.

Trends for different leisure contact reductions, when performing weekly universal testing, and importing 50 cases per day.

1.

Distribution of the number of infections for the experiments when the lock-down restrictions are continued.

2.

Distribution of the number of infections for the experiments when the lock-down restrictions are continued.

1.

Population size per household size and number of households per size: Belgian 2011 census and model population.

2.

Population size per household size and number of households per size: Belgian 2011 census and model population.

1.

Intravenous infection of chickens with Belgian H3N1 isolates: Clinical course, HI-titers, and virus antigen detection.

2.

Intravenous infection of chickens with Belgian H3N1 isolates: Clinical course, HI-titers, and virus antigen detection.

1.

Clinical phenotype of the affected puppies.

2.

Clinical phenotype of the affected puppies.

1.

Histopathological examination.

2.

Histopathological examination.

1.

Details of the Chr4:66,946,539_66,963,863del17,325 variant.

2.

Details of the Chr4:66,946,539_66,963,863del17,325 variant.

1.

Selenium concentrations in the blood of dogs with different SELENOP genotypes.

2.

Selenium concentrations in the blood of dogs with different SELENOP genotypes.

1.

Box 1: Eligibility criteria for PrEP reimbursement in Belgium (issued by the National institute for Health and Disability Insurance as of June 1, 2017).

2.

Box 1: Eligibility criteria for PrEP reimbursement in Belgium (issued by the National institute for Health and Disability Insurance as of June 1, 2017).

3.

Box 1: Eligibility criteria for PrEP reimbursement in Belgium (issued by the National institute for Health and Disability Insurance as of June 1, 2017).

4.

Box 1: Eligibility criteria for PrEP reimbursement in Belgium (issued by the National institute for Health and Disability Insurance as of June 1, 2017).

1.

Box 2: The MSM specific and high-risk group eligibility criteria adjusted to SSA migrants and operationalized by the TOGETHER data.

2.

Box 2: The MSM specific and high-risk group eligibility criteria adjusted to SSA migrants and operationalized by the TOGETHER data.

1.

Graph 3: Percentages of SSA migrants meeting the PrEP eligibility criteria*.

2.

Graph 3: Percentages of SSA migrants meeting the PrEP eligibility criteria*.

1.

Evolution of the bi-weekly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by Flemish province as a function of...

2.

Evolution of the bi-weekly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by Flemish province as a function of...

3.

Evolution of the bi-weekly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by Flemish province as a function of...

4.

Evolution of the bi-weekly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by Flemish province as a function of...

5.

Evolution of the bi-weekly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by Flemish province as a function of...

6.

Evolution of the bi-weekly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by Flemish province as a function of...

1.

S2 Fig -

2.

S2 Fig -

3.

S2 Fig -

4.

S2 Fig -

5.

S2 Fig -

6.

S2 Fig -

7.

S2 Fig -

8.

S2 Fig -

1.

Evolution of the mean log-transformed viral load in positive patients screened pre-hospitalization/pre-surgery by Flemish province as a function of time (from 1 April 2020 to 31 Ma...

2.

Evolution of the mean log-transformed viral load in positive patients screened pre-hospitalization/pre-surgery by Flemish province as a function of time (from 1 April 2020 to 31 Ma...

3.

Evolution of the mean log-transformed viral load in positive patients screened pre-hospitalization/pre-surgery by Flemish province as a function of time (from 1 April 2020 to 31 Ma...

4.

Evolution of the mean log-transformed viral load in positive patients screened pre-hospitalization/pre-surgery by Flemish province as a function of time (from 1 April 2020 to 31 Ma...

5.

Evolution of the mean log-transformed viral load in positive patients screened pre-hospitalization/pre-surgery by Flemish province as a function of time (from 1 April 2020 to 31 Ma...

6.

Evolution of the mean log-transformed viral load in positive patients screened pre-hospitalization/pre-surgery by Flemish province as a function of time (from 1 April 2020 to 31 Ma...

1.

S4 Fig -

2.

S4 Fig -

3.

S4 Fig -

4.

S4 Fig -

5.

S4 Fig -

6.

S4 Fig -

7.

S4 Fig -

8.

S4 Fig -

9.

S4 Fig -

1.

Evolution of the monthly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by ten-year age group as a function of...

2.

Evolution of the monthly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by ten-year age group as a function of...

3.

Evolution of the monthly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by ten-year age group as a function of...

4.

Evolution of the monthly SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by ten-year age group as a function of...

1.

Boxplots showing the evolution of the (distribution of the) log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by month (from 1 April 202...

2.

Boxplots showing the evolution of the (distribution of the) log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by month (from 1 April 202...

3.

Boxplots showing the evolution of the (distribution of the) log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by month (from 1 April 202...

4.

Boxplots showing the evolution of the (distribution of the) log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by month (from 1 April 202...

1.

Boxplots of the log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by age (upper panel) and province (lower panel) with reported number o...

2.

Boxplots of the log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by age (upper panel) and province (lower panel) with reported number o...

3.

Boxplots of the log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by age (upper panel) and province (lower panel) with reported number o...

4.

Boxplots of the log-transformed viral load (in copies/mL) for SARS-CoV-2 positive a-/pre-symptomatic patients by age (upper panel) and province (lower panel) with reported number o...

1.

Estimated evolution of the SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by province for individuals aged 54...

2.

Estimated evolution of the SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by province for individuals aged 54...

3.

Estimated evolution of the SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by province for individuals aged 54...

4.

Estimated evolution of the SARS-CoV-2 real-time RT-PCR positivity ratio in a-/pre-symptomatic patients screened pre-hospitalization/pre-surgery by province for individuals aged 54...

1.

Illustration of delay cascading mechanism in the Dutch railways.

1.

S1 Fig -

2.

S1 Fig -

3.

S1 Fig -

4.

S1 Fig -

5.

S1 Fig -

6.

S1 Fig -

7.

S1 Fig -

1.

Additional file 2 of Management of a hospital-wide vancomycin-resistant Enterococcus faecium outbreak in a Dutch general hospital, 2014–2017: successful control using a restrictive...

1.

Additional file 3 of Management of a hospital-wide vancomycin-resistant Enterococcus faecium outbreak in a Dutch general hospital, 2014–2017: successful control using a restrictive...

1.

Consultation rates and chlamydia odds ratios from multivariable analysis by ethnicity.

2.

Consultation rates and chlamydia odds ratios from multivariable analysis by ethnicity.

3.

Consultation rates and chlamydia odds ratios from multivariable analysis by ethnicity.

1.

Schematic overview of the MILP-based schedule construction and validation phases before implementation.

1.

Original draft of EPA 6.

1.

Indispensability and comprehensiveness results of the 1 st Delphi round.

1.

Clarity results of the 1 st Delphi round.

1.

The revised EPA 6.

1.

Comparison of indispensability and comprehensiveness results of the 1 st and 2 nd Delphi round (revised EPAs only).

1.

Comparison of clarity results of the 1 st and 2 nd Delphi round (revised EPAs only).

1.

EPA 6: ‘Assessing and treating an acutely ill patient outside of the PICU’.

1.

Flow chart inclusion and exclusion process.

1.

Flowchart of the SaNAE study population.

1.

Percentage of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands who underwent SLNB (Sentinel Lymph Node Biopsy).

2.

Percentage of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands who underwent SLNB (Sentinel Lymph Node Biopsy).

3.

Percentage of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands who underwent SLNB (Sentinel Lymph Node Biopsy).

1.

Survival of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands diagnosed 2000–2016 followed up until Feb 2021 by SLNB (Sentinel Lym...

2.

Survival of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands diagnosed 2000–2016 followed up until Feb 2021 by SLNB (Sentinel Lym...

3.

Survival of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands diagnosed 2000–2016 followed up until Feb 2021 by SLNB (Sentinel Lym...

1.

Stringency government response in The Netherlands and Belgium.

2.

Stringency government response in The Netherlands and Belgium.

3.

Stringency government response in The Netherlands and Belgium.

4.

Stringency government response in The Netherlands and Belgium.

5.

Stringency government response in The Netherlands and Belgium.